Cargando…

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial

IMPORTANCE: Individuals living with schizophrenia are affected by cardiometabolic, endocrine, and motor adverse effects of current antipsychotic medications. Lumateperone is a serotonin, dopamine, and glutamate modulator with the potential to treat schizophrenia with few adverse effects. OBJECTIVE:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Correll, Christoph U., Davis, Robert E., Weingart, Michal, Saillard, Jelena, O’Gorman, Cedric, Kane, John M., Lieberman, Jeffrey A., Tamminga, Carol A., Mates, Sharon, Vanover, Kimberly E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990963/ https://www.ncbi.nlm.nih.gov/pubmed/31913424 http://dx.doi.org/10.1001/jamapsychiatry.2019.4379

Ejemplares similares

S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY
por: Vanover, Kimberly, et al.
Publicado: (2018)

F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA
por: Davis, Robert, et al.
Publicado: (2018)

Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
por: Vanover, Kimberly E., et al.
Publicado: (2018)

T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS
por: Durgam, Suresh, et al.
Publicado: (2020)

M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY
por: Satlin, Andrew, et al.
Publicado: (2020)

Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials
por: Kane, John M, et al.
Publicado: (2021)

S221. THE EFFICACY OF LUMATEPERONE 42 MG IN THE TREATMENT OF SCHIZOPHRENIA SYMPTOMS ASSOCIATED WITH SOCIAL FUNCTIONING: POST HOC ANALYSIS OF AN ACUTE PLACEBO- AND ACTIVE-CONTROLLED TRIAL
por: Vanover, Kimberly, et al.
Publicado: (2020)

The role of lumateperone in the treatment of schizophrenia
por: Syed, Alveena Batool, et al.
Publicado: (2021)

Pharmacologic treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2010)

Illuminating Hope for Mental Health: A Drug Review on Lumateperone
por: Tarzian, Martin, et al.
Publicado: (2023)

Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats
por: Snyder, Gretchen L., et al.
Publicado: (2016)

Lumateperone Normalizes Pathological Levels of Acute Inflammation through Important Pathways Known to Be Involved in Mood Regulation
por: Dutheil, Sophie, et al.
Publicado: (2023)

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
por: Tiihonen, Jari, et al.
Publicado: (2019)

New synthesis of a late-stage tetracyclic key intermediate of lumateperone
por: Milen, Mátyás, et al.
Publicado: (2022)

Management of subjects with Intermittent Explosive Disorder and Autism Spectrum Disorder with Lumateperone
por: Mehdiratta, N., et al.
Publicado: (2023)

Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
por: Snyder, Gretchen L., et al.
Publicado: (2014)

Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?
por: Barman, Rajdip, et al.
Publicado: (2021)

Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives
por: Correll, Christoph U., et al.
Publicado: (2011)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past,  Present and Future
por: Li, Peng, et al.
Publicado: (2016)

Atypical Antipsychotic Lumateperone Effects on the Adrenal Gland With Possible Beneficial Effect of Quercetin Co-administration
por: El-Haroun, Hala, et al.
Publicado: (2021)

F250. DEPRESSION IN SCHIZOPHRENIA: CORRELATIONS WITH OBJECTIVE AND SUBJECTIVE QUALITY OF LIFE OUTCOMES
por: Harvey, Philip, et al.
Publicado: (2018)

Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review
por: CORRELL, Christoph U., et al.
Publicado: (2016)

The biology of schizophrenia
por: Tamminga, Carol A., et al.
Publicado: (2000)

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
por: Kane, John M., et al.
Publicado: (2021)

Clinical predictors of therapeutic response to antipsychotics in schizophrenia
por: Carbon, Maren, et al.
Publicado: (2014)

Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
por: Loebel, Antony, et al.
Publicado: (2015)

Role of 5-HT(2A) receptor antagonists in the treatment of insomnia
por: Vanover, Kimberly E, et al.
Publicado: (2010)

International Congress on Schizophrenia Research: Introduction
por: Tamminga, Carol A., et al.
Publicado: (2007)

Treatment-refractory schizophrenia
por: Caspi, Asaf, et al.
Publicado: (2004)

Studies in schizophrenia: pathophysiology and treatment
por: Tamminga, Carol A., et al.
Publicado: (2002)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia
por: Meyer, Jonathan M., et al.
Publicado: (2023)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

PM421. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies
por: Skuban, Aleksandar, et al.
Publicado: (2016)

Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review
por: Coles, Alexandria S., et al.
Publicado: (2021)

Validated Bayesian Differentiation of Causative and Passenger Mutations
por: Cross, Frederick R., et al.
Publicado: (2017)

Association of Low-Dose Quetiapine and Diabetes
por: Højlund, Mikkel, et al.
Publicado: (2021)

Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
por: Correll, Christoph U, et al.
Publicado: (2020)

New Developments in the Treatment of Schizophrenia: An Expert Roundtable
por: Kantrowitz, Joshua T, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v513qj3uasklgqvbhe76d6ii1b